Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $850.4 million.

  • Avidity Biosciences' Cash from Financing Activities rose 14830.81% to $850.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.8 million, marking a year-over-year decrease of 2814.68%. This contributed to the annual value of $1.2 billion for FY2024, which is 117030.28% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Cash from Financing Activities is $850.4 million, which was up 14830.81% from $3.8 million recorded in Q2 2025.
  • Avidity Biosciences' Cash from Financing Activities' 5-year high stood at $850.4 million during Q3 2025, with a 5-year trough of $17000.0 in Q1 2021.
  • For the 5-year period, Avidity Biosciences' Cash from Financing Activities averaged around $140.3 million, with its median value being $31.9 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 9989.9% in 2023, then surged by 85606000.0% in 2024.
  • Over the past 5 years, Avidity Biosciences' Cash from Financing Activities (Quarter) stood at $20.7 million in 2021, then surged by 1076.28% to $243.7 million in 2022, then plummeted by 86.91% to $31.9 million in 2023, then crashed by 56.97% to $13.7 million in 2024, then surged by 6096.2% to $850.4 million in 2025.
  • Its last three reported values are $850.4 million in Q3 2025, $3.8 million for Q2 2025, and $1.9 million during Q1 2025.